These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36882021)

  • 1. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
    Yan ZJ; Yu CT; Chen L; Wang HY
    Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
    Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
    Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
    Kou L; Xie X; Chen X; Li B; Li J; Li Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
    Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
    Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma.
    Goggi JL; Ramasamy B; Tan YX; Hartimath SV; Tang JR; Cheng P; Msallam R; Chacko AM; Hwang YY; Robins EG
    Mol Imaging; 2021; 2021():9305277. PubMed ID: 35936114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
    Chen X; Kou L; Xie X; Su S; Li J; Li Y
    Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.